What is OCX's gross margin?

OncoCyte (OCX) has a gross margin of 66% and a net margin of -4711%.

What is OCX's P/E ratio?

Track OncoCyte (OCX) P/E ratio, ROE, and valuation metrics over time.

Where can I see OCX's full financials?

See OncoCyte (OCX) income statement, cash flow, and balance sheet — quarterly and annual — alongside insider trading activity.

OncoCyte (OCX) Financials — Revenue, Earnings, Cash Flow

$3.20

Last traded 2025-07-14 — delisted

NASDAQ · Healthcare · Biotechnology · $91.5M mcap · 8M float · 0.924% daily turnover · Short 61% of daily vol

Overview News Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Dividends Analysis Technicals Weather Peers ESG Institutions Dark Pool Short Interest Supply Chain

📊 Key Metrics

TTM

$2M

Revenue

-60.8% YoY

$-49M

Net Income

+22.2% YoY

$-26M

Free Cash Flow

-9.8% YoY

65.7%

Gross Margin

-4770.7%

Op. Margin

-4711.3%

Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE488.7%

ROA-123.5%

ROIC109.1%

Valuation

P/E-2.1

P/B-5.5

EV/EBITDA-4.4

Leverage

Debt/Equity-0.12

Current Ratio2.00

Interest Cov.-270.6x

Quality Scores

Piotroski F2/9

Altman Z-19.30

Beneish M-7.33